Samuel S. Hahn, MD, FACC, FSCAI

Yale-New Haven Health System Designates Tirofiban as the Primary Glycoprotein IIb/IIIa Inhibitor

04/26/2017

Given the therapeutic equivalence, we have saved approximately $125K in the past 12 months by switching to tirofiban just at Yale-New Haven Hospital. The savings system-wide are even higher.

Given the therapeutic...

04/26/2017

Cath Lab Digest

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

November 13 ⁠–⁠ November 16

November 13 ⁠–⁠ November 16

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

December 12 ⁠–⁠ December 13

December 14 ⁠–⁠ December 15

February 2 ⁠–⁠ February 5

See Full Calendar

Samuel S. Hahn, MD, FACC, FSCAI

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products